Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?
Metformin has been used for treating diabetes mellitus since the late 1950s. In addition to its antihyperglycemic activity, it was shown to be a potential drug candidate for treating a range of other diseases that include various cancers, cardiovascular diseases, diabetic kidney disease, neurodegene...
Main Authors: | Varda Shoshan-Barmatz, Uttpal Anand, Edna Nahon-Crystal, Marta Di Carlo, Anna Shteinfer-Kuzmine |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2021.730048/full |
Similar Items
-
VDAC1: From structure to cancer therapy
by: Varda eShoshan-Barmatz, et al.
Published: (2012-11-01) -
VDAC1 at the Intersection of Cell Metabolism, Apoptosis, and Diseases
by: Varda Shoshan-Barmatz, et al.
Published: (2020-10-01) -
Selective induction of cancer cell death by VDAC1‐based peptides and their potential use in cancer therapy
by: Anna Shteinfer‐Kuzmine, et al.
Published: (2018-06-01) -
VDAC1 at the crossroads of cell metabolism, apoptosis and cell stress
by: Varda Shoshan-Barmatz, et al.
Published: (2017-09-01) -
Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
by: Tasleem Arif, et al.
Published: (2018-12-01)